Weight Loss Drugs May Help Prevent Addiction and Overdoses, Research Reveals
A groundbreaking study has found that weight loss drugs, specifically GLP-1 receptor agonists like Mounjaro and Ozempic, could potentially reduce the risk of addiction to substances such as alcohol, tobacco, cannabis, and cocaine. Published in the British Medical Journal, the research suggests these medications might also lower the chances of overdose, hospitalization, or death among individuals already using illicit drugs.
How GLP-1s Influence Brain Pathways
GLP-1 receptor agonists, primarily used to treat type 2 diabetes and obesity, are believed to work by affecting the brain's reward pathways, thereby curbing cravings. These drugs mimic natural substances released after eating, helping users feel fuller and reducing the desire for addictive substances.
The US study analyzed data from 606,434 veterans with type 2 diabetes over up to three years. Compared to those on other diabetes medications like sodium-glucose cotransporter-2 drugs, GLP-1s were associated with significant reductions in substance use risks:
- Alcohol-related disorders: 18% lower risk
- Cannabis use: 14% lower risk
- Cocaine use: 20% lower risk
- Nicotine use: 20% lower risk
- Opioid use: 25% lower risk
Additionally, for people already using substances, GLP-1s reduced the risk of overdose by 39%, emergency department visits by 31%, and death by 50%.
Expert Insights and Cautionary Notes
Professor Claire Anderson, president of the Royal Pharmaceutical Society, which represents 35,500 UK pharmacists, commented on the findings. "This study adds to emerging research exploring whether GLP-1 medicines may influence brain pathways involved in reward and addiction," she said. However, she emphasized that as an observational study, it does not prove these drugs can prevent or treat addiction directly. "Further research, including clinical trials, will be needed to understand whether GLP-1 medicines have a direct effect," Anderson added.
Gareth Jones, director of corporate affairs at the National Pharmacy Association, highlighted the potential benefits. "This is a significant study and shows that weight loss treatment may have potential to give important additional therapeutic benefits," he stated. Jones noted that while more is being understood about the long-term impacts of GLP-1s, they can positively affect various health outcomes for eligible patients. He also pointed out that the NHS's rollout of these drugs for obesity remains "painfully slow" despite the significant health issues obesity causes.
Challenges and Side Effects of GLP-1 Use
Despite the promising findings, challenges persist with GLP-1 medications. A separate meta-analysis by Cambridge University, published in eClinical Medicine, found that most people who stop taking these drugs regain 60% of lost weight within a year and 75% eventually, sustaining only 25% of weight loss long-term. The authors explained that this gradual regain means a sustained weight reduction of around 5% for someone who initially lost 20% of their weight.
Approximately half of users discontinue GLP-1s within a year, and 75% stop after two years, often due to side effects like nausea and high costs. Moreover, a survey by Simple Online Pharmacy of over 3,000 GLP-1 users revealed that two-thirds hide their use from friends and family, fearing judgment. Among those criticized, 79% were accused of taking "the easy way out" and 68% were told to "just eat less and move more."
This research underscores the potential dual benefits of weight loss drugs in managing obesity and reducing addiction risks, but it also highlights the need for further studies and improved access to these treatments.
